Literature DB >> 1278069

The problem of non-compliance in long-term antihypertensive therapy.

J D Abernethy.   

Abstract

Of 1,593 subjects admitted to the Australian National Blood Pressure Study 1 to 2 years ago, a substantial number (391 or 24.5%) ceased attending, in 85% of cases voluntarily. Withdrawal rates were very high in the first 4 months, settling to 5% per annum by the second year. Extrapolation to clinical practice is hazardous but contibutory factors elicited by questionnaire suggest certain management strategies: maximisation of efforts to enlist subject co-operation at the onset of treatment; management of treatment by family doctor or health centre with appointments flexible in time and infrequent in number; minimisation of doctors' ambivalence about treatment effectiveness and the withholding of information from the subject. It is inevitable that a proportion of subjects will reject long-term drug treatment. This adds further weight to the need for research on alternatives such as low salt diets.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1278069     DOI: 10.2165/00003495-197600111-00022

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  3 in total

Review 1.  Survival distribution.

Authors:  V A Clark
Journal:  Annu Rev Biophys Bioeng       Date:  1975

2.  The Australian National Blood Pressure Study.

Authors:  J D Abernethy
Journal:  Med J Aust       Date:  1974-05-25       Impact factor: 7.738

3.  Cardiovascular diseases.

Authors:  D L Sackett
Journal:  Lancet       Date:  1974-11-16       Impact factor: 79.321

  3 in total
  3 in total

1.  Fourteen fallacies about patient package inserts.

Authors:  J Goyan
Journal:  West J Med       Date:  1981-05

Review 2.  A social-psychological perspective on successful community control of high blood pressure: a review.

Authors:  S V Kasl
Journal:  J Behav Med       Date:  1978-12

3.  Nadolol in combination with indapamide and xipamide in resistant hypertensives.

Authors:  S Dean; M J Kendall; S Potter; M H Thompson; D A Jackson
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.